Currently out of the existing stock ratings of Kyle Mikson, 182 are a BUY (83.11%), 37 are a HOLD (16.89%).

Kyle Mikson

Work Performance Price Targets & Ratings Chart

Analyst Kyle Mikson, currently employed at CANACCORD, carries an average stock price target met ratio of 57.95% that have a potential upside of 33.67% achieved within 263 days. Previously, Kyle Mikson worked at CANTOR FITZGERALD.

Kyle Mikson’s has documented 414 price targets and ratings displayed on 23 stocks. The coverage is on Healthcare, Basic Materials, Industrials sectors.

Most recent stock forecast was given on BDSX, Biodesix at 18-Jun-2026.

Wall Street Analyst Kyle Mikson

Analyst best performing recommendations are on TTOO (T2 BIOSYSTMS).
The best stock recommendation documented was for TTOO (T2 BIOSYSTMS) at 4/29/2024. The price target of $3 was fulfilled within 1 day with a profit of $0.16 (5.63%) receiving and performance score of 56.34.

Average potential price target upside

of $31.85 (41.63%) on NTRA (NATERA).
of $24.69 (34.29%) on EXAS (EXACT SCIENCES).
of $18 (13.35%) on RGEN (REPLIGEN).

BDSX Biodesix ILMN Illumina LUCD Lucid Diagnostics NTRA Natera PACB Pacific Biosciences of California QSI QuantumSi XGN Exagen CSTL Castle Biosciences EXAS EXACT Sciences GH Guardant Health NSTG NanoString Technologies QTRX Quanterix Corp TTOO T2 Biosystms SLGC Somalogic TX Ternium SA ADR AKYA Akoya Biosciences TXG 10X Genomics OLK Olink Holding AB ADR RGEN Repligen CAI CAI International BWAY Brainsway Ltd SLG SL Green Realty Corp TEM Tempus AI, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Kyle Mikson (CANACCORD)